title: Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?
authors.affiliation: Center of Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, G4200, 44 Binney St, Boston MA 02115, USA.
authors.forename: Martha R
authors.initials: MR
authors.lastname: Neagu
authors.affiliation: Center of Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, G4200, 44 Binney St, Boston MA 02115, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
mesh_terms: D000068258:Bevacizumab / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D011173:Portraits as Topic; D012008:Recurrence; D022223:Vaccines, Subunit / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D000068258:Bevacizumab; C558237:rindopepimut
keywords: bevacizumab; epidermal growth factor receptor variant III; glioblastoma; rindopepimut; vaccine